iSpecimen Inc. Faces Delisting Concerns
Ticker: ISPC · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1558569
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
iSpecimen Inc. is on the verge of being delisted, major red flag.
AI Summary
iSpecimen Inc. filed an 8-K on November 21, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was November 19, 2025. The company is incorporated in Delaware and its principal executive offices are located in Woburn, MA.
Why It Matters
This filing indicates potential issues with iSpecimen Inc.'s continued listing on an exchange, which could significantly impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation and stock viability.
Key Players & Entities
- iSpecimen Inc. (company) — Registrant
- November 19, 2025 (date) — Earliest event reported
- November 21, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Woburn, MA (location) — Principal executive offices
FAQ
What specific listing rule or standard has iSpecimen Inc. failed to satisfy?
The filing does not specify the exact rule or standard that iSpecimen Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 19, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on November 21, 2025.
In which state is iSpecimen Inc. incorporated?
iSpecimen Inc. is incorporated in Delaware.
What is the address of iSpecimen Inc.'s principal executive offices?
The address of iSpecimen Inc.'s principal executive offices is 8 Cabot Road, Suite 1800, Woburn, MA 01801.
Filing Stats: 703 words · 3 min read · ~2 pages · Grade level 13.5 · Accepted 2025-11-21 17:20:34
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ISPC The Nasdaq Stock Mar
- $1.00 — common stock had been below the minimum $1.00 per share required for continued listin
Filing Documents
- ea0266546-8k_ispecimen.htm (8-K) — 26KB
- 0001213900-25-113708.txt ( ) — 190KB
- ispc-20251119.xsd (EX-101.SCH) — 3KB
- ispc-20251119_lab.xml (EX-101.LAB) — 33KB
- ispc-20251119_pre.xml (EX-101.PRE) — 22KB
- ea0266546-8k_ispecimen_htm.xml (XML) — 4KB
01. Notice of Delisting or Failure to Satisfy a
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2025, iSpecimen Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the closing bid price of the Company's common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") for the prior 30 consecutive business days. As a result, the Company is no longer in compliance with the Minimum Bid Price Requirement. The Notice has no immediate effect on the listing of the Company's common stock, which will continue to trade under the symbol "ISPC." Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial 180-calendar-day period, or until May 18, 2026, to regain compliance. If at any time before May 18, 2026, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of ten consecutive business days (or up to 20 consecutive business days if required by Nasdaq Staff), Nasdaq will notify the Company in writing that it has regained compliance and the matter will be closed. If the Company does not regain compliance by May 18, 2026, the Company may be eligible for an additional 180-day compliance period, provided it meets the continued listing standards for market value of publicly held shares and all other initial listing criteria for The Nasdaq Capital Market (other than the Minimum Bid Price Requirement), and notifies Nasdaq of its intent to cure the deficiency, which may include effectuating a reverse stock split. If the Company does not regain compliance within the applicable compliance period, the Company's common stock will be subject to delisting, and the Company would have the right to appeal any such determination to a Nasdaq